FMP
AMEX
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
24.86 USD
-0.0172 (-0.06919%)
Valuation Date:
Apr 22, 2024 11:31 AM
Share Price on Valuation Date
$24.86
Stock Beta
0.93
Shares Outstanding
466529